Drugs / JNJ-64991524
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03346122 | Nov 2017 → Nov 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64991524 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03346122 ↗ |
| Route | Oral | “single oral dose (Dose level 1)” NCT03346122 ↗ |